CN110507666A - A kind of new application of selenium lentinan - Google Patents
A kind of new application of selenium lentinan Download PDFInfo
- Publication number
- CN110507666A CN110507666A CN201910974802.5A CN201910974802A CN110507666A CN 110507666 A CN110507666 A CN 110507666A CN 201910974802 A CN201910974802 A CN 201910974802A CN 110507666 A CN110507666 A CN 110507666A
- Authority
- CN
- China
- Prior art keywords
- selenium
- lentinan
- alcoholic liver
- liver disease
- new application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of new application of selenium lentinan, the selenium lentinan is treated for alcoholic liver disease.The selenium lentinan is used to prepare alcoholic liver disease therapeutic agent.Prevention and treatment of the present invention research selenium lentinan to alcoholic liver disease, prominent selenium provide new means for the treatment of alcoholic liver disease, have expanded the application of selenium lentinan in the regulating and controlling effect and mechanism of alcoholic liver lesion.
Description
Technical field
The present invention relates to cell biologies and medical combined technology field, and in particular to a kind of new use of selenium lentinan
On the way.
Background technique
Alcoholic liver disease (ALD, alcoholic liver disease) is that liver organ caused by long-term drinking alcohol is suffered from
The general name of disease, morbidity and mortality rank among the best in the world.Alcoholic liver injury again can be according to the feature of morbidity
It is divided into steatosis, hepatitis, liver fibrosis, cirrhosis.Wherein, Severe degree hepatitis and cirrhosis are the main originals for causing death
Cause.The incidence and the death rate of hepatopathy caused by alcohol are in the state risen year by year.At present for the prevention and treatment of alcoholic liver disease one
Aspect is abstinence from alcohol, is on the other hand to be treated according to the degree of illness with composite medicine.Common clinical medicine has cortex class solid
Alcohol, pentoxifylline etc., but the side effect and adverse reaction that occur in therapeutic process are more, and most drugs are in pathology
There is no effect to alcoholic liver disease in detection points-scoring system.Therefore, novel effective liver protection is developed, liver-protecting medicine has very
Important meaning.
Lentinan (Lentinan LNT) is from Basidiomycota Pleurotaceae Agaricus fungi mushroom fruiting body (Lentinus
Edodes the glucan that separation and Extraction separates in).Research report confirms that lentinan has multi-biological as immunopotentiator
Activity, including the effects of immunological regulation, anti-oxidant, antibacterial, antiviral, anti-inflammatory and anticancer.
Selenium (selenium) is the essential trace elements of the human body, is played a significant role in the different physiological function of human body,
For the health maintenance of body, the prevention and treatment of disease has remarkable effect.Selenium is mainly with organic selenium (such as selenomethionine, seleno half
Cystine, γ-glutamyl Se- methylselenocysteine) and inorganic selenium (such as sodium selenate and sodium selenite) form exist.
Many epidemiology and clinical research show that the selenium of physiological level may have an extensive biological effect, including to heart disease,
Aging, oxidativestress damage even tumour have preventive and therapeutic effect.
Summary of the invention
It is an object of the invention to overcome the above-mentioned problems in the prior art, a kind of new use of selenium lentinan is provided
On the way, prevention and treatment of the research selenium lentinan to alcoholic liver disease, prominent selenium are wine in the regulating and controlling effect and mechanism of alcoholic liver lesion
The treatment of essence hepatopathy provides new means.
To achieve the above object, reach above-mentioned technical effect, the present invention is to be achieved through the following technical solutions:
A kind of new application of selenium lentinan, the selenium lentinan are treated for alcoholic liver disease.
As improvement to above-mentioned technical proposal, the selenium lentinan is used to prepare alcoholic liver disease therapeutic agent.
Compared with prior art, the advantages and positive effects of the present invention are:
The new application of selenium lentinan of the invention, studies prevention and treatment of the selenium lentinan to alcoholic liver disease, and prominent selenium exists
The regulating and controlling effect and mechanism of alcoholic liver lesion provide new means for the treatment of alcoholic liver disease, have expanded selenium lentinan
Application.
Detailed description of the invention
In order to more clearly explain the embodiment of the invention or the technical proposal in the existing technology, to embodiment or will show below
There is attached drawing needed in technical description to be briefly described, it should be apparent that, the accompanying drawings in the following description is only this
Some embodiments of invention without any creative labor, may be used also for those of ordinary skill in the art
To obtain other drawings based on these drawings.
Fig. 1 is cell inhibitory rate testing result schematic diagram of the present invention；
Fig. 2 is Apoptosis testing result schematic diagram；
Fig. 3 is ROS testing result schematic diagram；
Fig. 4 is mitochondrial membrane potential testing result schematic diagram.
Specific embodiment
Following will be combined with the drawings in the embodiments of the present invention, and technical solution in the embodiment of the present invention carries out clear, complete
Site preparation description, it is clear that described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.It is based on
Embodiment in the present invention, it is obtained by those of ordinary skill in the art without making creative efforts every other
Embodiment, any modification, equivalent replacement, improvement and so on should all be included in the protection scope of the present invention.
Human normal hepatocyte strain LO2 cell culture is intervened in advance in DMEM+10%FBS, while using selenium lentinan
After 6h, 400mM alcohol intervene cell for 24 hours, the film potential variation of the proliferation of cell, apoptosis, ROS and mitochondria is detected
As a result as follows:
1, compared with Control group, 400mM ethyl alcohol seriously inhibits cell Proliferation；And sodium selenite, lentinan and selenium are fragrant
Mushroom polysaccharide can significantly restore the proliferative capacity (P < 0.01) of cell；Selenium lentinan is significantly higher than the protective effect of cell
Sodium selenite and lentinan group (P < 0.01).As shown in Figure 1, Eth is alcohol in Fig. 1；LNT is lentinan；Se-len
For selenium lentinan,**It indicates compared with Eth group, difference has statistical significance (P < 0.01)；##It indicates and Se-len (10 μ
M) group compares, and difference has statistical significance (P < 0.01).
2, compared with Control group, 400mM ethyl alcohol promotes Apoptosis (P < 0.01)；Compared with ethanol group, selenous acid
Sodium, lentinan and selenium lentinan can significantly inhibit Apoptosis (P < 0.01)；Suppression of the selenium lentinan to Apoptosis
Production is with being significantly higher than sodium selenite and lentinan group (P < 0.01).As shown in Figure 2.In Fig. 2,**It indicates compared with Eth group,
Difference has statistical significance (P < 0.01)；##It indicates compared with Se-len (10 μM) group, difference has statistical significance (P <
0.01)
3, compared with Control group, 400mM ethyl alcohol promotes the raising (P < 0.01) of cell ROS and mitochondrial membrane potential；
Compared with ethanol group, sodium selenite, lentinan and selenium lentinan can significantly inhibit cell ROS and mitochondrial membrane potential (P
< 0.01)；Selenium lentinan is significantly higher than sodium selenite and lentinan to the inhibiting effect of cell ROS, mitochondrial membrane potential
Group (P < 0.01).As shown in Figure 3-4.Wherein in Fig. 3, * * is indicated compared with Eth group, and difference has statistical significance (P <
0.01)；## indicates that compared with Se-len (10 μM) group, difference has statistical significance (P < 0.01).In Fig. 4, * * indicate with
Eth group compares, and difference has statistical significance (P < 0.01)；## indicates that compared with Se-len (10 μM) group, difference has statistics
It learns meaning (P < 0.01).
Intervene alcohol damaged LO2 cell model using selenium lentinan to find: selenium lentinan can significantly inhibit alcohol
To the inhibiting effect of the proliferation of LO2, apoptosis ratio is reduced, the release of ROS and the variation of mitochondrial membrane potential are inhibited；It is more with mushroom
Sugar is compared, and inhibiting effect becomes apparent from, and implies that selenium lentinan inhibits alcoholic liver disease more effective.
The foregoing is merely presently preferred embodiments of the present invention, is not intended to limit the invention, for ordinary skill
All within the principle of the present invention for personnel, any modification, equivalent substitution, improvement and etc. done should be included in the present invention
Protection scope within.
Claims (2)
1. a kind of new application of selenium lentinan, it is characterised in that: the selenium lentinan is treated for alcoholic liver disease.
2. the new application of selenium lentinan as described in claim 1, it is characterised in that: the selenium lentinan is used to prepare wine
Essence hepatosis treating medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910974802.5A CN110507666A (en) | 2019-10-14 | 2019-10-14 | A kind of new application of selenium lentinan |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910974802.5A CN110507666A (en) | 2019-10-14 | 2019-10-14 | A kind of new application of selenium lentinan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110507666A true CN110507666A (en) | 2019-11-29 |
Family
ID=68634311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910974802.5A Pending CN110507666A (en) | 2019-10-14 | 2019-10-14 | A kind of new application of selenium lentinan |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110507666A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050287230A1 (en) * | 2004-06-25 | 2005-12-29 | Jeffrey Young | Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof |
| CN101766306A (en) * | 2009-01-05 | 2010-07-07 | 王星丽 | Body-beautifying flammukinan health capsule |
| CN108456259A (en) * | 2018-05-02 | 2018-08-28 | 福建医科大学 | Application of the anoectochilus roxburghii polyose in acute alcohol-induced hepatic injury drug |
-
2019
- 2019-10-14 CN CN201910974802.5A patent/CN110507666A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050287230A1 (en) * | 2004-06-25 | 2005-12-29 | Jeffrey Young | Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof |
| CN101766306A (en) * | 2009-01-05 | 2010-07-07 | 王星丽 | Body-beautifying flammukinan health capsule |
| CN108456259A (en) * | 2018-05-02 | 2018-08-28 | 福建医科大学 | Application of the anoectochilus roxburghii polyose in acute alcohol-induced hepatic injury drug |
Non-Patent Citations (3)
| Title |
|---|
| 任广明: "香菇多糖的硒化及其对慢性胰腺炎小鼠肠道菌群的影响", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
| 张素云等: "硒对酒精性肝损害小鼠保护作用的研究", 《现代中西医结合杂志》 * |
| 钟萍等: "香菇多糖对酒精性肝损伤小鼠自由基及TNF-α 含量的影响", 《山西医科大学学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106075120B (en) | A kind of Eczema Creams agent | |
| Kim et al. | Physical, chemical, and biological properties of wonder kelp—Laminaria | |
| CN108371642B (en) | Spring balance water and preparation method thereof | |
| WO2009145345A1 (en) | Preparation for external use containing fungus of the genus cordyceps, cordyceps sobolifera (hill.) berk. et br. | |
| Wang et al. | Diversity of potentially exploitable pharmacological activities of the highly prized edible medicinal fungus Antrodia camphorata | |
| Rezaei et al. | Comparison of antioxidant and anti-inflammatory effects of honey and spirulina platensis with sulfasalazine and mesalazine on acetic acid-induced ulcerative colitis in rats | |
| CN111494466A (en) | A topical composition containing Cannabis sativa extract and its application | |
| JP2009108015A (en) | Inhibitor of stretch-mediated melanin production | |
| CN110507666A (en) | A kind of new application of selenium lentinan | |
| KR20110015171A (en) | Extract of soft corals and use thereof | |
| WO2015190875A1 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for preventing and treating retinal diseases | |
| CN102772471B (en) | Blueberry fruit peel extract and application thereof in preparation of anti-hepatic injury medicine | |
| CN108186494A (en) | A kind of natural plants toner | |
| Hartanto et al. | A comparative study of peel and seed extract of passion fruit (Passiflora edulis) as anti collagenase | |
| CN104940241B (en) | A kind of selenium worm grass compound preparation of prevention climacteric metancholia of women | |
| He et al. | Chemical constituents and biological activities of saponin from the seed of Camellia oleifera | |
| US20090098226A1 (en) | Composition for cosmetic or pharmaceutical-dermatological use | |
| TW201343194A (en) | Heparan sulfate production promoter | |
| CN108042663B (en) | Composition for whitening skin, removing freckles and preventing urinary system infection and preparation method and application thereof | |
| CN106727504B (en) | Application of simvastatin in preparation of medicine for preventing pulmonary oxygen poisoning caused by high partial pressure oxygen | |
| CN109674735A (en) | A kind of skin cream and preparation method thereof containing trollflower stem cell extract | |
| JP2014080373A (en) | Herpes simplex virus infection preventive/therapeutic agent from grifola frondosa extract | |
| CN108452229A (en) | Assist blood fat reducing preparation | |
| JP2010150216A (en) | Stress hormone action demulcent | |
| KR101924355B1 (en) | Composition for anti-stretch mark effect on the skin containing extracts of salicornia herbacea and ecklonia cava |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191129 |
|
| RJ01 | Rejection of invention patent application after publication |